Skip to main content

Table 3 Adverse events (>2% of patients overall) from a phase 2a study of ACC-001 in Japanese patients with mild-to-moderate Alzheimer’s disease[28]

From: Active immunotherapy options for Alzheimer’s disease

Event ACC-001 + QS-21 ACC-001 QS-21 (n = 6) PBS (n = 4)
  3 μg (n = 6) 10 μg (n = 6) 30 μg (n = 6) 10 μg (n = 6) 30 μg (n = 6)   
Any serious adverse eventa 1 (16.7) 0 1 (16.7) 0 0 0 0
Any adverse events 6 (100.0) 4 (66.7) 5 (83.3) 6 (100.0) 6 (100.0) 6 (100.0) 3 (75.0)
 Nasopharyngitis 2 (33.3) 2 (33.3) 2 (33.3) 0 3 (50.0) 1 (16.7) 2 (50.0)
 Injection site erythema 0 2 (33.3) 0 0 1 (16.7) 0 0
 Dental caries 0 1 (16.7) 0 1 (16.7) 1 (16.7) 0 1 (25.0)
 Protein urine present 1 (16.7) 1 (16.7) 0 0 1 (16.7) 0 0
 Glucose urine 1 (16.7) 0 0 1 (16.7) 0 0 1 (25.0)
 Cataract 1 (16.7) 0 0 1 (16.7) 0 0 1 (25.0)
 Contusion 1 (16.7) 0 0 1 (16.7) 0 1 (16.7) 0
 Back pain 0 0 1 (16.7) 0 1 (16.7) 0 0
 Blood triglyceride increased 0 1 (16.7) 1 (16.7) 0 0 1 (16.7) 0
 Injection site pain 0 1 (16.7) 1 (16.7) 0 0 0 0
 Pyrexia 0 1 (16.7) 0 0 1 (16.7) 0 0
 Delirium 1 (16.7) 0 0 0 0 1 (16.7) 0
 Blood pressure increased 0 0 0 1 (16.7) 0 1 (16.7) 0
 Eczema 0 1 (16.7) 0 0 0 0 1 (25.0)
  1. Data presented as n (%). PBS, phosphate-buffered saline. aAll patients.